News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
297,036 Results
Type
Article (16789)
Company Profile (285)
Press Release (279962)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (87368)
Career Advice (329)
Deals (14981)
Drug Delivery (38)
Drug Development (52241)
Employer Resources (37)
FDA (6492)
Job Trends (5827)
News (157050)
Policy (11128)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (3)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (1151)
Accelerated approval (2)
Adcomms (13)
Allergies (57)
Alliances (23635)
ALS (64)
Alzheimer's disease (877)
Antibody-drug conjugate (ADC) (89)
Approvals (6511)
Artificial intelligence (136)
Autoimmune disease (17)
Automation (6)
Bankruptcy (142)
Best Places to Work (5031)
BIOSECURE Act (5)
Biosimilars (45)
Biotechnology (235)
Bladder cancer (47)
Brain cancer (21)
Breast cancer (148)
Cancer (1403)
Cardiovascular disease (118)
Career advice (286)
Career pathing (9)
CAR-T (110)
Cell therapy (318)
Cervical cancer (8)
Clinical research (42371)
Collaboration (552)
Compensation (254)
Complete response letters (14)
COVID-19 (1139)
CRISPR (39)
C-suite (167)
Cystic fibrosis (77)
Data (1487)
Denatured (11)
Depression (32)
Diabetes (139)
Diagnostics (1672)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (10)
Drug discovery (87)
Drug pricing (28)
Drug shortages (5)
Duchenne muscular dystrophy (88)
Earnings (33102)
Editorial (21)
Employer branding (6)
Employer resources (34)
Events (50946)
Executive appointments (462)
FDA (7200)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (517)
Gene editing (94)
Generative AI (14)
Gene therapy (243)
GLP-1 (381)
Government (1232)
Grass and pollen (2)
Guidances (25)
Healthcare (7479)
Huntington's disease (22)
IgA nephropathy (22)
Immunology and inflammation (91)
Indications (20)
Infectious disease (1205)
Inflammatory bowel disease (113)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (65)
Interviews (58)
IPO (7935)
IRA (11)
Job creations (1093)
Job search strategy (240)
Kidney cancer (6)
Labor market (7)
Layoffs (242)
Leadership (6)
Legal (1632)
Liver cancer (32)
Lung cancer (195)
Lymphoma (93)
Machine learning (2)
Management (8)
Manufacturing (133)
MASH (51)
Medical device (3690)
Medtech (3691)
Mergers & acquisitions (7374)
Metabolic disorders (392)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (66)
Neuropsychiatric disorders (23)
Neuroscience (1282)
NextGen: Class of 2025 (2322)
Non-profit (1069)
Northern California (1695)
Now hiring (22)
Obesity (200)
Opinion (122)
Ovarian cancer (62)
Pain (43)
Pancreatic cancer (53)
Parkinson's disease (121)
Partnered (10)
Patents (138)
Patient recruitment (71)
Peanut (36)
People (27590)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14831)
Phase II (19609)
Phase III (12589)
Pipeline (809)
Policy (45)
Postmarket research (927)
Preclinical (6324)
Press Release (32)
Prostate cancer (65)
Psychedelics (35)
Radiopharmaceuticals (215)
Rare diseases (293)
Real estate (1683)
Recruiting (14)
Regulatory (9365)
Reports (16)
Research institute (1098)
Resumes & cover letters (44)
Rett syndrome (4)
RNA editing (4)
RSV (10)
Schizophrenia (61)
Series A (100)
Series B (63)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1489)
Special edition (11)
Spinal muscular atrophy (118)
Sponsored (15)
Startups (2120)
State (1)
Stomach cancer (4)
Supply chain (24)
Tariffs (5)
The Weekly (36)
United States (13368)
Vaccines (227)
Venture capitalists (30)
Weight loss (116)
Women's health (15)
Worklife (5)
Date
Today (15)
Last 7 days (280)
Last 30 days (1503)
Last 365 days (20737)
2025 (5809)
2024 (21857)
2023 (23901)
2022 (29544)
2021 (30066)
2020 (25764)
2019 (18454)
2018 (13485)
2017 (15360)
2016 (13432)
2015 (16200)
2014 (11638)
2013 (8638)
2012 (8684)
2011 (8862)
2010 (8481)
Location
Africa (185)
Alabama (44)
Alaska (2)
Arizona (64)
Arkansas (6)
Asia (18730)
Australia (3191)
California (3851)
Canada (1190)
China (339)
Colorado (151)
Connecticut (162)
Delaware (96)
Europe (41624)
Florida (495)
Georgia (123)
Idaho (16)
Illinois (244)
India (12)
Indiana (99)
Iowa (1)
Japan (100)
Kansas (64)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (480)
Massachusetts (3012)
Michigan (78)
Minnesota (174)
Mississippi (1)
Missouri (27)
Montana (14)
Nebraska (4)
Nevada (18)
New Hampshire (15)
New Jersey (987)
New Mexico (12)
New York (1046)
North Carolina (562)
North Dakota (4)
Northern California (1695)
Ohio (117)
Oklahoma (9)
Oregon (23)
Pennsylvania (750)
Puerto Rico (5)
Rhode Island (18)
South America (270)
South Carolina (4)
Southern California (1489)
Tennessee (27)
Texas (450)
Utah (57)
Virginia (77)
Washington D.C. (30)
Washington State (347)
Wisconsin (14)
297,036 Results for "structure therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ventus Therapeutics Announces Publication in Nature’s Communications Chemistry Describing the Structure-based Optimization of a New Series of cGAS Inhibitors
March 26, 2025
·
3 min read
Press Releases
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
January 30, 2025
·
1 min read
Press Releases
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights
February 27, 2025
·
10 min read
Press Releases
Cognito Therapeutics to Present New Data on Spectris’™ Impact on Brain Structure in Alzheimer’s Disease at AD/PD 2025
March 25, 2025
·
2 min read
Press Releases
Cognito Therapeutics Announces Spectris™ Data Demonstrating Brain Structural Maintenance and Mechanism of Action in Alzheimer’s Disease at AD/PD™ 2025
April 2, 2025
·
3 min read
Press Releases
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
November 15, 2024
·
1 min read
Press Releases
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
October 31, 2024
·
1 min read
Biotech Bay
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the pricing of its upsized underwritten public offering of 9,066,972 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $52.50 per ADS.
June 5, 2024
·
4 min read
Business
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate achievements.
May 9, 2024
·
8 min read
Press Releases
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
November 14, 2024
·
10 min read
1 of 29,704
Next
